NCT00524121

Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 65 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with radiation therapy works in treating older patients with stage I, stage II, stage III, or stage IV esophageal cancer.

Detailed description

OBJECTIVES: Primary * Assess the overall survival of older patients with stage I-IV squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction treated with erlotinib hydrochloride in combination with radiotherapy. Secondary * Assess the proportion of patients achieving mucosal complete response after treatment with this regimen. * Determine the progression-free survival of patients treated with this regimen. * Assess the effect of this regimen on dysphagia control, performance status, and overall quality of life of these patients. * Investigate the correlation between smoking status and overall survival of these patients. * To correlate the Epidermal growth factor receptor (EGFR) and phosphor Epidermal growth factor receptor (pEGFR) expression by IHC and EGFR mutation status with clinical outcomes. OUTLINE: This is a multicenter study. Patients receive oral erlotinib hydrochloride once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo external beam radiotherapy 5 days a week in weeks 1-4 or 5 days a week for the first 5.5 weeks. Tumor tissue samples are analyzed by IHC for the expression of E-cadherin, P-cadherin, vimentin, cytokeratin, phospho-S6, and Ki67. After completion of study treatment, patients are followed at 30 days and annually thereafter.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	erlotinib hydrochloride	Oral
OTHER	immunohistochemistry staining method	Correlative Study
RADIATION	radiation therapy	Radiation Treatment

Timeline

• Start date: 2006-03-01
• Primary completion: 2010-05-01
• Completion: 2011-10-01
• First posted: 2007-09-03
• Last updated: 2016-04-14
• Results posted: 2015-03-05

Locations

1 site across 1 country: United States